
Conference Coverage
Latest Content

Shorts










Podcasts
Videos
All News

In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went a median of 14.3 months without their disease worsening, compared with 8.3 months with immunotherapy plus chemotherapy.

Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.

In the phase 3 ADAURA trial, 79% of patients who took Tagrisso for three years after lung cancer surgery were alive at eight years, compared with 64% of patients who received a placebo.

Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung cancer. Here's what patients should know about three key studies.

Twenty-three years after a breast cancer diagnosis at 39, a survivor explains why her garage gym became a place to rebuild strength.

Diagnosed with peritoneal mesothelioma at 21 and given 18 months to live, a survivor reflects on what turning 40 means nearly two decades later.

Lung cancer treatment has changed rapidly since 2021, with new targeted drugs, immunotherapy and treatments designed to overcome resistance.

Most cancers now have at least three or four treatment approaches, and an oncologist explained how cancer heterogeneity shapes the way patients respond.

More than three years after cancer centers first sounded the alarm on chemotherapy shortages, the problem still hasn't gone away.

The FDA granted final approval to OMCAZIO, a new cabozantinib capsule formulation for certain patients with kidney, liver and neuroendocrine cancers.

Learn how to support a friend with cancer by showing up, listening, staying connected and treating them like the same person they were before diagnosis.

After 10 years of living with stage 4 ovarian cancer, one survivor shares why she continues to raise awareness each September and urges women to know the signs, make time for gynecologic care and advocate for themselves.

Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.

Medicare will narrow ostomy suppliers to about eight national contracts, and advocate Ellyn Mantell says a poor fit can put patients in the hospital.


























